Table 1.
SNP | Gene | Position | Genotype (%) | Counts | HR (CI 95%) | p Value* |
---|---|---|---|---|---|---|
GG (0.6) | 611 | Ref | ||||
rs1562302 | IL36B | chr2:113810458 | GA (0.36) | 363 | 0.70 (0.51 to 95) | |
AA (0.04) | 43 | 0.48 (0.17 to 1.30) | 0.026 | |||
AA (0.52) | 527 | Ref | ||||
rs2221903 | IL21 | chr4:123538912 | AG (0.39) | 394 | 1.19 (0.90 to 1.58) | |
GG (0.09) | 100 | 0.52 (0.28 to 0.97) | 0.016 | |||
CC (0.46) | 471 | Ref | ||||
rs2069840 | IL6 | chr7:22768572 | CG (0.45) | 456 | 0.59 (0.44 to 0.79) | |
GG (0.09) | 93 | 0.77 (0.48 to 1.22) | 0.0022 | |||
TT (0.24) | 247 | Ref | ||||
rs6783 | IL17D | chr13:21297050 | TC (0.52) | 522 | 0.64 (0.46 to 0.90) | |
CC (0.24) | 241 | 0.63 (0.42 to 0.95) | 0.024 | |||
CC (0.51) | 519 | Ref | ||||
rs7145531 | IL25 | chr14:23842017 | CT (0.42) | 426 | 1.39 (1.05 to 1.86) | |
TT (0.07) | 76 | 0.55 (0.28 to 1.08) | 0.0035 | |||
CC (0.46) | 466 | Ref | ||||
rs3811178 | IL25 | chr14:23845244 | CT (0.44) | 452 | 1.30 (0.98 to 1.74) | |
TT (0.10) | 100 | 0.70 (0.41 to 1.21) | 0.028 | |||
AA (0.41) | 414 | Ref | ||||
rs2292980 | IRF8 | chr16:85945076 | AG (0.48) | 490 | 0.68 (0.51 to 0.91) | |
GG (0.11) | 114 | 0.82 (0.51 to 1.33) | 0.038 | |||
AA (0.52) | 522 | Ref | ||||
rs12926854 | IRF8 | chr16:85951258 | AG (0.41) | 413 | 0.67 (0.50 to 0.90) | |
GG (0.07) | 72 | 0.98 (0.59 to 1.61) | 0.022 |
The results of multivariate analysis showing the most significant associations (p<0.05) between 72 tagging SNPs in 44 immunomodulatory genes and melanoma recurrence-free survival in 1022 melanoma patients ascertained at NYU Medical Center. The associations, HRs and 95% CIs were calculated using Cox regression models under two degrees of freedom test, adjusted by age at diagnosis, gender, stage, thickness, ulceration and histological subtype.
Of note, none of the associations with RFS reached Bonferroni level of significance (p<0.0007).
p Values were determined using two degrees of freedom test.
SNP, single nucleotide polymorphism.